Navigation Links
Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
Date:6/13/2011

SEATTLE, June 14, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it met with the U.S. Food and Drug Administration's (the "FDA") Division of Oncology Drug Products (the "DODP").  The meeting provided a pathway for re-submitting CTI's New Drug Application (the "NDA") for pixantrone for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") including the potential for accelerated approval based on the PIX301 study results. This meeting follows CTI's receipt of the FDA's Office of New Drugs' (the "OND") response to CTI's appeal as announced on May 3, 2011, which allows CTI the opportunity to resubmit the NDA. On appeal, the FDA recommended the Company conduct an additional review of radiographs utilizing a new independent panel of radiologists to confirm the response and progression events noted in the pixantrone NDA. The DODP meeting also focused on the documents CTI proposed to provide regarding the circumstances of stopping the enrollment of the clinical trial prior to achieving the original planned patient accrual and the make-up of the new radiology expert panel. CTI also plans to address items noted in the FDA's Complete Response Letter. The DODP confirmed that the NDA would be reviewed within six months from the resubmission of the NDA. CTI anticipates filing the additional information later this year, and could obtain FDA approval in the first half of 2012.

"We are pleased to have the opportunity to meet with the review team from the DODP and to get their feedback on what will be required for a resubmission of our pixantrone NDA. We now have a pathway to move forward with resubmitting the NDA for potential accelerated approval of pixantrone in patients with multiple relapsed or refractory aggressive NHL, which is a stage of this disease for which there are no approved agents," stated Jack W. Singer, M.D., Chief Medical Officer of CTI. "We are excited to have been given this rare second o
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
2. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
3. Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
4. Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China
5. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
6. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
7. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
8. Echo Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference
9. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
10. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
11. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  Sage Analytics ( www.sageanalytics.com ), the ... the testing of marijuana potency and moisture content, ... Profiler, the industry,s first product suite capable of ... portable unit. Designed from the ground ... cannabis industry, the Luminary™ Profiler utilizes specially purposed ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... robust development with the growth pace keeping at 20%-30% in ... the size of China separating membrane ... to 16.3%. It is projected that China ... around 20% in the upcoming years and that the figure ... An integrated membrane industrial system has taken shape in ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... shows that loss of Arf gene in presence ... growth-enhancing environment of the bone,marrow, helping cells develop ... Tenn., Aug. 29 Results of a study,by ... strong,evidence for why the drug imatinib (Gleevec(TM)), which ...
... First-In-Human Study to Cancer Patients, SALT LAKE ... that its first-in-humans Phase 1 study of PRLX ... evaluate the safety,pharmacokinetic and pharmacodynamic properties of PRLX ... include TGen Clinical Research at,Scottsdale Healthcare in Scottsdale, ...
Cached Medicine Technology:St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia 2Prolexys Pharmaceuticals Initiates Phase 1 Study 2
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Traveling through the ... measles virus to three others within a four-hour time ... a new report shows. "The exposures in this ... rather than an international terminal, highlighting the fact that ... Jared Vega, an infectious disease specialist at the U.S. ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... for at least 20 seconds you may be at risk ... one leg may indicate that small strokes or tiny bleeds ... strokes is high, the investigators reported online Dec. 18 in ... standing on one leg, as well as problems walking, should ...
(Date:12/17/2014)... 2014 Dr. Myo Nwe is the co-author ... of the Future” and co-founder of the Ace Medical Weight ... Nwe takes a broad look at the industry of weight ... scientific scrutiny. On film and in television shows, however, she ... the social aspects and played for basic laughs, which she ...
(Date:12/17/2014)... RI (PRWEB) December 17, 2014 ... recognize private practices that have made outstanding and ... in support and progression of private practice physical ... American Physical Therapy Association. , On behalf of ... OCS, owner and CEO of Performance accepted the ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 A group of ... for Longevity, today, in reaction to a recent statement by ... of brain training and derogated the efficacy of all brain ... agreed with the parts of the center’s statement critical of ... the center had also overstated its case, in a document ...
Breaking Medicine News(10 mins):Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... WASHINGTON, Sept. 16 The Amputee Coalition of America and ... Tom Harkin and Olympia J. Snowe and Representatives Robert E. ... joint organizations, 2009 Legislative Appreciation Awards. , , ... http://www.prnewswire.com/mnr/aopa/40117/ , , (Photo: ...
... , , Prostate ... , DENVER, Sept. 16 This September, the Prostate ... take lifesaving measures. In just 10 minutes, the same amount ... screened for prostate cancer, the second leading cause of death among ...
... , , , NORWALK, ... theft protection services, today announced the availability of new features in its ... damaging types of identity theft: medical identity theft. , , ... if personal health records containing inaccurate information are used by health care ...
... WASHINGTON, Sept. 16 While research shows many American children become ... is reversing the trend by motivating them to be more physically ... To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/ccna/39748/ ... launched in 2005 by Boys & Girls Clubs of America (BGCA) ...
... , , PITTSBURGH, Sept. 16 Mylan ... privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative ... the President,s Emergency Plan for AIDS Relief (PEPFAR) for its ... Fumarate Tablets, 600 mg/300 mg/300 mg. , , ...
... , , , ... business of beauty and there was nothing more beautiful at the ... donated by designers such as Giorgio Armani, Tadashi and Luca Luca. ... and even created a Limited Edition Clarisonic just for the occasion. ...
Cached Medicine News:Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 3Health News:Free Screenings During Prostate Cancer Awareness Week 2Health News:Free Screenings During Prostate Cancer Awareness Week 3Health News:Affinion Security Center Launches Benefits to Help Detect and Resolve Medical Identity Theft 2Health News:Affinion Security Center Launches Benefits to Help Detect and Resolve Medical Identity Theft 3Health News:Video: Teen Girls Less Active, but Triple Play Program Bucks Trend 2Health News:Video: Teen Girls Less Active, but Triple Play Program Bucks Trend 3Health News:Video: Teen Girls Less Active, but Triple Play Program Bucks Trend 4Health News:Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets 2Health News:Brooke Burke Debuts Limited Edition 'Couture' Clarisonic on Ultimate Style Stage: The SGK Pink Dress Runway at New York Fashion Week 2Health News:Brooke Burke Debuts Limited Edition 'Couture' Clarisonic on Ultimate Style Stage: The SGK Pink Dress Runway at New York Fashion Week 3
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
15" overall length, 9" handle....
9.5" overall length, 4.5" handle....
...
Medicine Products: